Mos from RTX start, median (IQR) | 7.5 (6–11.5) [442] | 6.5 (6–8.5) [128] | < 0.0001 |
Age, yrs | 49.5 ± 11.8 [439] | 51.1 ± 12.6 [125] | 0.19 |
Female, % | 88 [442] | 85 [128] | 0.39 |
Disease duration, yrs, median (IQR) | 9 (5–15) [439] | 10 (5–16) [125] | 0.98 |
RF+, % | 79 [382] | 79 [104] | 0.99 |
Anti-CCP+, % | 78 [138] | 66 [58] | 0.06 |
No. previous csDMARD | 2.4 ± 1.2 [430] | 2.5 ± 1.5 [119] | 0.36 |
No. previous bDMARD | 0.5 ± 0.7 [432] | 0.6 ± 0.7 [118] | 0.22 |
DAS28 at RTX start | 6.3 ± 1.0 [414] | 6.1 ± 1.2 [122] | 0.03 |
Baseline DAS28 | 5.1 ± 1.3 [424] | 4.1 ± 1.4 [120] | < 0.0001 |
DAS28 improvement from RTX start | −1.0 ± 1.9 [414] | −1.9 ± 1.5 [122] | < 0.0001 |
Baseline HAQ | 1.5 ± 0.7 [355] | 1.3 ± 0.8 [90] | 0.001 |
Concomitant csDMARD | 82 [442] | 92 [128] | 0.005 |
Concomitant corticosteroids | 58 [442] | 46 [128] | 0.004 |
RTX dose at baseline, 1000 mg × 2, % | 91.2 [432] | 89.1 [128] | 0.46 |